We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly investors haven't had much to celebrate so far in 2025. On Jan. 14, shares of Lilly ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

Key Takeaways JNJ will buy Intra-Cellular Therapies, producer of a drug for bipolar disorder, for $14.6 billion. Eli Lilly ...

Bank of America, Morgan Stanley earnings more than double for Q4. BAC stock and MS shares are closing in on buy points.

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed ...

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

Eli Lilly and Company’s LLY shares declined 6.6% on Tuesday after the company lowered its sales guidance for full-year 2024 ...

U.S. stock futures point higher ahead of closely watched CPI report, JPMorgan Chase stock rises on better-than-expected ...

Here are some of the biggest premarket US stock movers today: Goldman Sachs (NYSE: GS) stock rose 2.2% after the investment bank’s profit more than doubled in the fourth quarter, driven by strong ...